Previous Article
Infection and Immunity, June 1999, p. 3175-3179, Vol. 67, No. 6
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Lymphotoxin Inhibits Chlamydia
pneumoniae Growth in HEp-2 Cells
Hiroshi
Matsushima,1,2
Mutsunori
Shirai,1
Kazunobu
Ouchi,3
Kenji
Yamashita,4
Tetsu
Kakutani,4
Susumu
Furukawa,2 and
Teruko
Nakazawa1,*
Department of
Microbiology1 and Department of
Pediatrics,2 Yamaguchi University School of
Medicine, Ube, Yamaguchi 755-8505, Saiseikai Shimonoseki
General Hospital, Shimonoseki 751-0823,3 and
Kanegafuchi Chemical Industry Co., Takasago, Hyogo
676-8688,4 Japan
Received 3 November 1998/Returned for modification 13 January
1999/Accepted 12 March 1999
 |
ABSTRACT |
Cytokines such as gamma interferon and tumor necrosis factor alpha
(TNF-
) inhibit the intracellular replication of Chlamydia pneumoniae or Chlamydia trachomatis. In this study,
we found that another cytokine, lymphotoxin (TNF-
), restricts the
growth of C. pneumoniae in HEp-2 cells. When lymphotoxin
(10 U/ml) was added during incubation from 8 to 16 h
postinoculation, inclusion body formation was severely reduced. In
addition, we observed activation of nitric oxide production and the
nuclear transition of NF-
B in HEp-2 cells in response to
lymphotoxin. These results suggest that inhibition of chlamydial growth
by lymphotoxin is mediated, at least in part, by nuclear transition of
NF-
B, resulting in induction of nitric oxide synthase to produce
nitric oxide, a potent bacteristatic agent. This is the first report on
antichlamydial activity of lymphotoxin through induction of nitric oxide.
 |
TEXT |
Chlamydia pneumoniae is
an obligate intracellular bacterium that can cause upper and lower
respiratory tract infections in humans (15). In addition,
infection with this microorganism has been associated with chronic
inflammatory diseases such as asthma (17) and
atherosclerosis (26). Recent reports on isolation of
C. pneumoniae from specimens of coronary artery atheroma
(33) and carotid artery atheroma (20) further
implicate the bacterium as a causative agent of atherosclerosis.
Various cytokines have been demonstrated to restrict the growth of
intracellular pathogens and are significant activators of host cell
immune responses to infections. Gamma interferon (IFN-
) has been
implicated in chlamydial control in humans and experimental animals
(3, 4, 6, 7, 18, 22). The biochemical basis of the
antichlamydial action of IFN-
may include the induction of
intracellular enzymes such as inducible nitric oxide synthase (iNOS) in
rodent (22, 27) and indoleamine-2,3-dioxygenase (IDO), which
in turn activates host cell tryptophan catabolism in humans (3, 6,
7, 28, 38). In addition to IFN-
, tumor necrosis factor alpha
(TNF-
) is a mediator of inflammation and plays a role in host
defense against C. trachomatis infection (9, 35,
41). In various cell types, both IFN-
and TNF-
activate
iNOS, which catalyzes the conversion of L-arginine to citrulline and nitric oxide (NO), an important antimicrobial and tumoricidal agent as well as a cell signaling molecule (2, 24, 29,
39). Nevertheless, the reports regarding the relative roles of
iNOS and other mechanisms of cytokine-mediated inhibition of
intracellular chlamydial growth have, in general, been categorized according to whether they have involved rodent systems (iNOS) or human
systems (IDO).
Lymphotoxin (LT), a cytokine secreted by activated macrophages and
lymphocytes (13), has approximately 30% homology in its amino acid sequence to TNF-
(31). LT and TNF-
are
encoded by closely linked genes that are included in the human major
histocompatibility complex (37), share a common cell surface
receptor, p55 (1, 30), and have similar biological
activities (14). Thus, LT has also been called TNF-
(34). In addition, both TNF-
and LT activate a nuclear
transcription factor, NF-
B, in human macrophage-like U-937 cells
(8). In the present study, we tested whether LT is also
implicated in the growth of C. pneumoniae. Our findings show
that LT has antichlamydial activity that may be mediated by nuclear
transition of NF-
B, resulting in the induction of iNOS. This is the
first report that LT has antichlamydial activity and iNOS plays a role
in the antichlamydial system in humans.
Determination of chlamydial growth.
HEp-2 (ATCC CCL 23) cells
were allowed to adhere to 96-well tissue culture plates and grown in
Iscove's modified Dulbecco's medium (GIBCO) supplemented with 5%
fetal calf serum and gentamicin (50 µg/ml) for 72 h prior to use.
C. pneumoniae TW183 (Washington Research Foundation,
Seattle) was passaged, titrated, and stored at
80°C until use. The
stock chlamydial suspension was diluted in phosphate-buffered saline, and a 0.2-ml aliquot (1.5 × 103 inclusion-forming
units [IFU]) was added to monolayers. Infection was established by
centrifugation (700 × g) at 22°C for 1 h,
followed by incubation at 36°C in a 5% CO2 atmosphere
for 1 h. Then the inoculum was aspirated and replaced with a
medium consisting of Iscove's modified Dulbecco's medium, 10% fetal
calf serum, cycloheximide (1.5 µg/ml), and gentamicin (50 µg/ml)
(CP medium). LT was purified from culture supernatant of CHO cells
transfected with human LT genomic DNA as described previously
(11).
The infected HEp-2 cells grown in CP medium were incubated with LT at
for an 8-h period before or after inoculation. At the end of each
period, the cells were washed once with and placed in fresh prewarmed
CP medium and then incubated for up to 48 h.
The infected monolayers were fixed for 15 min in 95% ethanol and
stained with a
C. pneumoniae-specific monoclonal antibody
(RR402; 400-fold dilution; Washington Research Foundation) and
fluorescein isothiocyanate-labeled goat anti-mouse immunoglobulins
(20-fold dilution; DAKO, Glostrup, Denmark). Cells were examined
under
a fluorescence microscope at a magnification of ×100 for
IFU,
determined on the basis of the average numbers of inclusion
bodies per
field determined from three fields per well from triplicate
samples.
Percent inhibition of chlamydial growth was calculated
[(IFU of
control)

(IFU of treated sample)/(IFU of control)]
×
100.
Values are expressed as means ± standard errors of the mean of
triplicate assays. Student's unpaired
t tests were used to
assess the statistical significance of differences.
P values
of
less than 0.05 were considered
significant.
Effect of LT on chlamydial growth.
Studies were carried out to
determine whether LT affects the infectivity and/or replication of
C. pneumoniae in HEp-2 cells. Incubation with LT (10 U/ml)
for 8 h from 0 to 8 h, 8 to 16 h, or 16 to 24 h
postinoculation reduced the growth of C. pneumoniae at
48 h postinoculation by 70, 77, or 62%, respectively, whereas little inhibition was observed by incubation with LT for 8 h from 24 to 32 h, 32 to 40 h, or 40 to 48 h postinoculation
(Fig. 1A). Chlamydial growth was not
affected when the HEp-2 cells were treated with LT for 8 h or
chlamydial microorganisms were treated with LT for 1 h just prior
to inoculation. A titration curve of LT on chlamydial growth revealed
that LT at concentrations above 10 U per ml inhibited growth (Fig. 1B).
Since L-tryptophan is reported to rescue C. pneumoniae from the bacteristatic effect of IFN-
(38), we tested whether exogenous tryptophan reduced LT-mediated inhibition of chlamydial growth. When C. pneumoniae-infected cells were incubated with LT in the absence or
presence of various concentrations of L-tryptophan,
chlamydial growth was similarly reduced (Fig. 1C).

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 1.
(A) Inhibition of chlamydial growth by LT in HEp-2
cells. C. pneumoniae elementary bodies were treated with LT
(10 U/ml) for 1 h prior to infection (EB+LT), or confluent HEp-2
monolayers were infected with C. pneumoniae, and LT (10 U/ml) was added at indicated time periods for 8 h before or after
infection. Incubations were carried out at 36°C for 48 h
postinoculation in a 5% CO2 atmosphere. (B) Dose-dependent
inhibition of chlamydial growth by LT in HEp-2 cells. LT was added for
8 h from 8 to 16 h postinoculation. (C) Effect of tryptophan
on antichlamydial activity of LT. LT (10 U/ml) alone or with tryptophan
(0 [open bars], 1 [hatched bars], 10 [stippled bars], or 100 [filled bars] µg per ml) was added to HEp-2 cells pre- or
postinoculation. Incubations were carried out for 36 h
postinoculation. Chlamydial growth was determined with a C. pneumoniae-specific monoclonal antibody under a fluorescence
microscope (magnification, ×100). Inhibition of chlamydial growth is
expressed as percent inhibition ± standard error. Differences in
comparison with the untreated control in panels A and B were
significant (*, P < 0.001).
|
|
Growth of C. pneumoniae in BHK cells producing LT.
To assess the effect of endogenously produced LT on chlamydial
infectivity, we constructed a plasmid, pLT-R3, containing the human LT
gene to obtain stable transfectants carrying the human LT gene (Fig.
2A). DNA transfection and selection of
stable transformants were carried out according to the method of
Yamashita et al. (43). After a 2-week incubation of
BHK-21(C-13) (ATCC CCL 10) cells transfected with micromolar amounts of
pLT-R3 DNA, two stable transformants, BHK-110 and BHK-175, were
obtained.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 2.
(A) Structure of plasmid pLT-R3, carrying the human LT
gene (human LT), the Escherichia coli guanine
phosphoribosyltransferase gene (gpt), and the -lactamase
gene (bla) on a pUC replicon. The human LT gene has the
native promoter sequence (TATAAA). Three tandemly repeated
enhancer sequences are derived from the long terminal repeat sequence
of Rous sarcoma virus (E). The start codon (ATG), the stop codon (TAG),
and the polyadenylation signal (AATAAA) for LT are also
indicated. Plasmid pLT was constructed from pSV2gpt, pUC12, and an
EcoRI fragment containing human LT gene by several
sequential steps (43). Then the EcoRI fragment
from pSVcat (12) containing the long terminal repeat of Rous
sarcoma virus was inserted into the EcoRI site of pLT
located upstream from the LT promoter in the sense direction to produce
plasmid pLT-R3. (B) Inhibition of chlamydial growth in LT-producing
cells. Confluent cell monolayers were infected with C. pneumoniae and incubated for 36 h. Growth of C. pneumoniae was determined as described in the legend to Fig. 1 and
is expressed as percent inhibition ± standard error. Differences
in experimental groups were significant (*, P < 0.01).
|
|
The inhibition of IFU in the transfectants was about 80% at 36 h
postinoculation (Fig.
2B), close to that in HEp-2 cells incubated
with
10 U of LT per ml (Fig.
1B). These results suggest that extracellular
LT produced by the transfectants inhibits chlamydial growth, although
it remains possible that intracellular LT directly inhibits growth.
In
a separate experiment, we determined LT by an L-M cell (ATCC
CCL 1.2)
lytic assay (
43). The transfectants BHK-175 and BHK-110
produced LT in 24-h culture supernatants at levels of 64 to 128
and 32 to 64 U per ml, respectively, whereas nontransfected BHK-21
and HEp-2
cells did not produce detectable levels of LT. Thus,
the inhibition of
chlamydial growth in LT-producing cells appeared
to be lower than that
expected from the levels of LT produced,
possibly due to the difference
in responsiveness to LT between
BHK cells and HEp-2 cells. Based on
these results, we concluded
that chlamydia-susceptible cells could be
transformed to low-susceptibility
cells by introducing the LT
gene.
Role of NO in antichlamydial activity of LT.
Since
antichlamydial cytokines such as TNF-
and IFN-
induce iNOS, we
tested whether LT also induces iNOS in infected cells. HEp-2 cells were
treated with LT in the presence of
N-guanidino-monomethyl-L-arginine acetate (MLA;
WAKO, Osaka, Japan), a specific inhibitor of NO synthase
(24). Cycloheximide was omitted from the medium when MLA was
added. Cells were grown in 96-well tissue culture plates, infected with
1.5 × 103 IFU of C. pneumoniae per well,
and incubated at 36°C for 48 h. NO production was assessed by
determining nitrite concentrations in culture supernatant by using
Griess reagent as described previously (16).
Nitrite levels in the supernatants of HEp-2 cells uninfected or
infected with
C. pneumoniae increased three- to fivefold
when
LT was added (Fig.
3A). When the NO
synthase inhibitor MLA was
added with LT, the nitrite levels were
reduced to less than 20%.
In accordance with these observations, the
chlamydial growth inhibited
by LT was rescued significantly by adding
MLA (Fig.
3B). Based
on these results, we concluded that LT exhibits
antichlamydial
activity, at least in part, by inducing NO synthesis.
These results
provided initial evidence that iNOS plays a role in the
antichlamydial
system in humans.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 3.
(A) NO production by LT-treated HEp-2 cells without or
with C. pneumoniae infection and its inhibition by MLA.
HEp-2 cells noninfected or infected with C. pneumoniae were
incubated with LT (10 or 160 U/ml) without (open bars) or with (filled
bars) 1 mM MLA. After 48 h of incubation, the concentration of
nitrite in the supernatant was determined with a spectrophotometric
assay using Griess reagent. Nitrite concentrations are expressed as
means ± standard errors of triplicate wells. Differences in
experimental groups were significant (*, P < 0.05;
**, P < 0.01). (B) Inhibition of chlamydial growth by LT
in the absence or presence of MLA. HEp-2 cells received LT (10 or 160 U/ml) without (open bars) or with (filled bars) 1 mM MLA just after
inoculation of C. pneumoniae. Inhibition of chlamydial
growth was determined as described in the legend to Fig. 1 and is
expressed as percent inhibition ± standard error. Differences in
experimental groups were significant (*, P < 0.01).
|
|
Nuclear transition of NF-
B in HEp-2 cells treated with LT.
Since induction of iNOS is dependent on NF-
B that is activated for
transport to the nucleus (23), we determined the effect of
LT on nuclear transition of NF-
B by an indirect method with a rabbit
anti-human NF-
B antibody (Santa Cruz Biotechnology, Santa Cruz,
Calif.) and fluorescein-labeled goat anti-rabbit immunoglobulin. When
examined under a fluorescence microscope, HEp-2 cells treated for 15 min with LT at concentrations from 7.25 to 116 U per ml showed
significant nuclear transition of NF-
B, whereas cells treated with
LT at concentrations below 3.63 U per ml did not show the nuclear
transition even after prolonged incubation (data not shown). These
results suggested that LT treatment activates NF-
B, which in turn
may activate iNOS.
In this study, we showed that LT treatment of
C. pneumoniae-infected HEp-2 cells markedly reduced the formation of
inclusion
bodies. The highest inhibition was observed when LT was
present
for 8 h from 8 to 16 h postinoculation (Fig.
1A),
which may correspond
to the time period of chlamydial replication
(
5).
Previous studies have demonstrated that IFN-

or TNF-

reduces
chlamydial infectivity in vitro (
3,
4,
35,
38). However,
there has been no report on the effect of LT (TNF-

) on chlamydial
infectivity. Many mammalian cells show sensitivity to LT or express
the
receptors for LT (or TNF) (
14,
31). BHK-21 cells also
express the receptor for LT (
44), and HEp-2 cells were found
to be responsive to LT in this study. LT as well as TNF-

and
IFN-

are strong activators of NF-

B (
8), a transcriptional
enhancer as well as a critical component in the signal transduction
pathways leading to induction of iNOS (
42). We have shown
for
the first time that LT efficiently induces iNOS in vitro in HEp-2
cells either without or with
C. pneumoniae infection (Fig.
3A).
Since the antichlamydial activity of LT was partially suppressed
by adding MLA, an NO synthase inhibitor (Fig.
3B), NO seemed to
play a
role in the antichlamydial activity. Furthermore, LT induced
nuclear
transition of NF-

B in HEp-2 cells, suggesting that the
NF-

B-mediated induction of iNOS (
42) is involved in
antichlamydial
activity.
When HEp-2 cells were treated with LT for 8 h just prior to
C. pneumoniae inoculation, infectivity was not affected
(Fig.
1A), suggesting that the LT-primed NO production, even if lasting
after removal of LT, was not sufficient to suppress the infection.
The
marked antichlamydial effect of LT added at the first 8-h
period may be
due to the inhibition of induced phagocytosis of
elementary bodies,
their transformation to reticulate bodies,
and/or initiation of
replication of reticulate bodies. However,
there are several equally
plausible explanations for the antichlamydial
effects of NO, including
inhibition of chlamydial DNA replication
and inhibition of host cell
respiration (
5,
10,
24,
25,
29,
40).
Tryptophan is an essential amino acid for chlamydiae, and it has been
suggested that its intracellular pool decreases as a
consequence of
enzymatic degradation by IFN-

-induced IDO, resulting
in restriction
of chlamydial growth to a persistent state (
3,
4). The
antichlamydial activity of IFN-

alone or with TNF-
can be
suppressed by the addition of tryptophan (
3,
6,
36,
38). In
contrast, elevation of tryptophan concentrations in
the medium did not
affect the anti-
C. pneumoniae activity of LT,
as shown in
this study. Therefore, we concluded that the induction
of IDO may not
be a major cause of the antichlamydial activity
of LT observed in this
study.
It should be noted that the addition of MLA did not result in complete
blocking of the antichlamydial activity of LT (Fig.
3B), suggesting
that iNOS induction may not be the sole mechanism
for the inhibition of
chlamydial growth by LT. Recent studies
on iNOS knockout mice indicated
that iNOS is dispensable for the
removal of
C. trachomatis
from the genital epithelium (
18).
TNF-

has been shown to
induce low amounts of mRNA for IFN-

,
an antiviral agent, in HEp-2
cells (
21). We assessed the anti-
C. pneumoniae
activity of other cytokines, including IFN-

, IFN-

,
and
granulocyte colony-stimulating factor, and found that these
cytokines
failed to suppress intracellular growth of chlamydiae
(data not shown).
LT and TNF-

share a common surface receptor
subunit, p55, but
TNF-

requires additionally subunit p75 for
its binding
(
19). It is possible that these cytokines exert
antichlamydial effects via different
mechanisms.
Further investigations on the function of LT and the intracellular fate
of
C. pneumoniae may shed light on the mechanism of
persistent infection and lead to the development of new therapeutic
approaches toward the treatment of atherosclerosis mediated by
C. pneumoniae infection.
 |
ACKNOWLEDGMENTS |
This study was supported by a Grant-in-Aid for Scientific Research
from the Ministry of Education, Science, Culture and Sports of Japan
(G09877059) and by a grant from the Japan Society for the Promotion of
Science (JSPS-FRTF97L00101).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology, Yamaguchi University School of Medicine, Ube, Yamaguchi 755-8505, Japan. Phone: 81-836-22-2226. Fax: 81-836-22-2415. E-mail: nakazawa{at}po.cc.yamaguchi-u.ac.jp.
Editor:
J. R. McGhee
 |
REFERENCES |
| 1.
|
Aggarwal, B. B.,
T. E. Eessalu, and P. E. Hass.
1985.
Characterization of receptors for human tumour necrosis factor and their regulation by -interferon.
Nature
318:665-667[Medline].
|
| 2.
|
Amber, I. J.,
J. B. Hibbs, Jr.,
R. R. Taintor, and Z. Vavrin.
1988.
Cytokines induce an L-arginine-dependent effector system in nonmacrophage cells.
J. Leukoc. Biol.
44:58-65[Abstract].
|
| 3.
|
Beatty, W. L.,
T. A. Belanger,
A. A. Desai,
R. P. Morrison, and G. I. Byrne.
1994.
Tryptophan depletion as a mechanism of gamma interferon-mediated chlamydial persistence.
Infect. Immun.
62:3705-3711[Abstract/Free Full Text].
|
| 4.
|
Beatty, W. L.,
G. I. Byrne, and R. P. Morrison.
1993.
Morphologic and antigenic characterization of interferon -mediated persistent Chlamydia trachomatis infection in vitro.
Proc. Natl. Acad. Sci. USA
90:3998-4002[Abstract/Free Full Text].
|
| 5.
|
Beatty, W. L.,
R. P. Morrison, and G. I. Byrne.
1994.
Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis.
Microbiol. Rev.
58:686-699[Abstract/Free Full Text].
|
| 6.
|
Byrne, G. I.,
L. K. Lehmann, and G. J. Landry.
1986.
Induction of tryptophan catabolism is the mechanism for gamma-interferon-mediated inhibition of intracellular Chlamydia psittaci replication in T24 cells.
Infect. Immun.
53:347-351[Abstract/Free Full Text].
|
| 7.
|
Carlin, J. M., and J. B. Weller.
1995.
Potentiation of interferon-mediated inhibition of Chlamydia infection by interleukin-1 in human macrophage cultures.
Infect. Immun.
63:1870-1875[Abstract].
|
| 8.
|
Chaturvedi, M. M.,
M. Higuchi, and B. B. Aggarwal.
1994.
Effect of tumor necrosis factors, interferons, interleukins, and growth factors on the activation of NF- B: evidence for lack of correlation with cell proliferation.
Lymphokine Cytokine Res.
13:309-313[Medline].
|
| 9.
|
Darville, T.,
K. K. Laffoon,
L. R. Kishen, and R. G. Rank.
1995.
Tumor necrosis factor alpha activity in genital tract secretions of guinea pigs infected with chlamydiae.
Infect. Immun.
63:4675-4681[Abstract].
|
| 10.
|
Drapier, J.-C., and J. B. Hibbs, Jr.
1988.
Differentiation of murine macrophages to express nonspecific cytotoxicity for tumor cells results in L-arginine-dependent inhibition of mitochondrial iron-sulfur enzymes in the macrophage effector cells.
J. Immunol.
140:2829-2838[Abstract].
|
| 11.
|
Fukushima, K.,
H. Watanabe,
K. Takeo,
M. Nomura,
T. Asahi, and K. Yamashita.
1993.
N-linked sugar chain structure of recombinant human lymphotoxin produced by CHO cells: the functional role of carbohydrate as to its lectin-like character and clearance velocity.
Arch. Biochem. Biophys.
304:144-153[Medline].
|
| 12.
|
Gorman, C. M.,
G. T. Merlino,
M. C. Willingham,
I. Pastan, and B. H. Howard.
1982.
The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection.
Proc. Natl. Acad. Sci. USA
79:6777-6781[Abstract/Free Full Text].
|
| 13.
|
Granger, G. A., and T. W. Williams.
1968.
Lymphocyte cytotoxicity in vitro: activation and release of a cytotoxic factor.
Nature
218:1253-1254[Medline].
|
| 14.
|
Gray, P. W.,
B. B. Aggarwal,
C. V. Benton,
T. S. Bringman,
W. J. Henzel,
J. A. Jarrett,
D. W. Leung,
B. Moffat,
P. Ng,
L. P. Svedersky,
M. A. Palladino, and G. E. Nedwin.
1984.
Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity.
Nature
312:721-724[Medline].
|
| 15.
|
Grayston, J. T.
1992.
Infections caused by Chlamydia pneumoniae, strain TWAR.
Clin. Infect. Dis.
15:757-763[Medline].
|
| 16.
|
Green, S. J.,
J. Aniagolu, and J. J. Raney.
1994.
Oxidative metabolism of murine macrophages, p. 14.5.1-14.5.11.
In
J. E. Coligan (ed.), Current protocols in immunology. John Wiley & Sons, Inc., New York, N.Y.
|
| 17.
|
Hahn, D. L.,
R. W. Dodge, and R. Golubjatnikov.
1991.
Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma.
JAMA
266:225-230[Abstract/Free Full Text].
|
| 18.
|
Igietseme, J. U.,
L. L. Perry,
G. A. Ananaba,
I. M. Uriri,
O. O. Ojior,
S. N. Kumar, and H. D. Caldwell.
1998.
Chlamydial infection in inducible nitric oxide synthase knockout mice.
Infect. Immun.
66:1282-1286[Abstract/Free Full Text].
|
| 19.
|
Iwamoto, S.,
I. Shibuya,
K. Takeda, and M. Takeda.
1994.
Lymphotoxin lacks effects on 75-kDa receptors in cytotoxicity on U-937 cells.
Biochem. Biophys. Res. Commun.
199:70-77[Medline].
|
| 20.
|
Jackson, L. A.,
L. A. Campbell,
C.-C. Kuo,
D. I. Rodriguez,
A. Lee, and J. T. Grayston.
1997.
Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen.
J. Infect. Dis.
176:292-295[Medline].
|
| 21.
|
Jacobsen, H.,
J. Mestan,
S. Mittnacht, and C. W. Dieffenbach.
1989.
Beta interferon subtype 1 induction by tumor necrosis factor.
Mol. Cell. Biol.
9:3037-3042[Abstract/Free Full Text].
|
| 22.
|
Johansson, M.,
K. Schön,
M. Ward, and N. Lycke.
1997.
Genital tract infection with Chlamydia trachomatis fails to induce protective immunity in gamma interferon receptor-deficient mice despite a strong local immunoglobulin A response.
Infect. Immun.
65:1032-1044[Abstract].
|
| 23.
|
Kleinert, H.,
C. Euchenhofer,
I. Ihrig-Biedert, and U. Förstermann.
1996.
In murine 3T3 fibroblasts, different second messenger pathways resulting in the induction of NO synthase II (iNOS) converge in the activation of transcription factor NF- B.
J. Biol. Chem.
271:6039-6044[Abstract/Free Full Text].
|
| 24.
|
Knowles, R. G., and S. Moncada.
1994.
Nitric oxide synthases in mammals.
Biochem. J.
298:249-258.
|
| 25.
|
Lepoivre, M.,
B. Chenais,
A. Yapo,
G. Lemaire,
L. Thelander, and J.-P. Tenu.
1990.
Alterations of ribonucleotide reductase activity following induction of the nitrite-generating pathway in adenocarcinoma cells.
J. Biol. Chem.
265:14143-14149[Abstract/Free Full Text].
|
| 26.
|
Linnanmäki, E.,
M. Leinonen,
K. Mattila,
M. S. Nieminen,
V. Valtonen, and P. Saikku.
1993.
Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease.
Circulation
87:1130-1134[Abstract/Free Full Text].
|
| 27.
|
Mayer, J.,
M. L. Woods,
Z. Vavrin, and J. B. Hibbs, Jr.
1993.
Gamma interferon-induced nitric oxide production reduces Chlamydia trachomatis infectivity in McCoy cells.
Infect. Immun.
61:491-497[Abstract/Free Full Text].
|
| 28.
|
Murray, H. W.,
A. Szuro-Sudol,
D. Wellner,
M. J. Oca,
A. M. Granger,
D. M. Libby,
C. D. Rothermel, and B. Y. Rubin.
1989.
Role of tryptophan degradation in respiratory burst-independent antimicrobial activity of gamma interferon-stimulated human macrophages.
Infect. Immun.
57:845-849[Abstract/Free Full Text].
|
| 29.
|
Nathan, C.
1992.
Nitric oxide as a secretory product of mammalian cells.
FASEB J.
6:3051-3064[Abstract].
|
| 30.
|
Patton, J. S.,
H. M. Shepard,
H. Wilking,
G. Lewis,
B. B. Aggarwal,
T. E. Eessalu,
L. A. Gavin, and C. Grunfeld.
1986.
Interferons and tumor necrosis factors have similar catabolic effects on 3T3 L1 cells.
Proc. Natl. Acad. Sci. USA
83:8313-8317[Abstract/Free Full Text].
|
| 31.
|
Pennica, D.,
G. E. Nedwin,
J. S. Hayflick,
P. H. Seeburg,
R. Derynck,
M. A. Palladino,
W. J. Kohr,
B. B. Aggarwal, and D. V. Goeddel.
1984.
Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin.
Nature
312:724-729[Medline].
|
| 32.
|
Puolakkainen, M.,
C.-C. Kuo,
A. Shor,
S.-P. Wang,
J. T. Grayston, and L. A. Campbell.
1993.
Serological response to Chlamydia pneumoniae in adults with coronary arterial fatty streaks and fibrolipid plaques.
J. Clin. Microbiol.
31:2212-2214[Abstract/Free Full Text].
|
| 33.
|
Ramirez, J. A.,
S. Ahkee,
J. T. Summersgill,
B. L. Ganzel,
L. L. Ogden,
T. C. Quinn,
C. A. Gaydos,
L. L. Bobo,
M. R. Hammerschlag,
P. M. Roblin,
W. LeBar,
J. T. Grayston,
C.-C. Kuo,
L. A. Campbell,
D. L. Patton,
D. Dean, and J. Schachter.
1996.
Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis.
Ann. Intern. Med.
125:979-982[Abstract/Free Full Text].
|
| 34.
|
Shalaby, M. R.,
B. B. Aggarwal,
E. Rinderknecht,
L. P. Svedersky,
B. S. Finkle, and M. A. Palladino, Jr.
1985.
Activated of human polymorphonuclear neutrophil functions by interferon- and tumor necrosis factors.
J. Immunol.
135:2069-2073[Abstract].
|
| 35.
|
Shemer-Avni, Y.,
D. Wallach, and I. Sarov.
1988.
Inhibition of Chlamydia trachomatis growth by recombinant tumor necrosis factor.
Infect. Immun.
56:2503-2506[Abstract/Free Full Text].
|
| 36.
|
Shemer-Avni, Y.,
D. Wallach, and I. Sarov.
1989.
Reversion of the antichlamydial effect of tumor necrosis factor by tryptophan and antibodies to beta interferon.
Infect. Immun.
57:3484-3490[Abstract/Free Full Text].
|
| 37.
|
Spies, T.,
C. C. Morton,
S. A. Nedospasov,
W. Fiers,
D. Pious, and J. L. Strominger.
1986.
Genes for the tumor necrosis factors and are linked to the human major histocompatibility complex.
Proc. Natl. Acad. Sci. USA
83:8699-8702[Abstract/Free Full Text].
|
| 38.
|
Summersgill, J. T.,
N. N. Sahney,
C. A. Gaydos,
T. C. Quinn, and J. A. Ramirez.
1995.
Inhibition of Chlamydia pneumoniae growth in HEp-2 cells pretreated with gamma interferon and tumor necrosis factor alpha.
Infect. Immun.
63:2801-2803[Abstract].
|
| 39.
|
Wei, X.-Q.,
I. G. Charles,
A. Smith,
J. Ure,
G.-J. Feng,
F.-P. Huang,
D. Xu,
W. Mullar,
S. Moncada, and F. Y. Liew.
1995.
Altered immune responses in mice lacking inducible nitric oxide synthase.
Nature
375:408-411[Medline].
|
| 40.
|
Wharton, M.,
D. L. Granger, and D. T. Durack.
1988.
Mitochondrial iron loss from leukemia cells injured by macrophages.
J. Immunol.
141:1311-1317[Abstract].
|
| 41.
|
Williams, D. M.,
D. M. Magee,
L. F. Bonewald,
J. G. Smith,
C. A. Bleicker,
G. I. Byrne, and J. Schachter.
1990.
A role in vivo for tumor necrosis factor alpha in host defense against Chlamydia trachomatis.
Infect. Immun.
58:1572-1576[Abstract/Free Full Text].
|
| 42.
|
Xie, Q.-W.,
Y. Kashiwabara, and C. Nathan.
1994.
Role of transcription factor NF- B/Rel in induction of nitric oxide synthase.
J. Biol. Chem.
269:4705-4708[Abstract/Free Full Text].
|
| 43.
|
Yamashita, K.,
Y. Ikenaka,
T. Kakutani,
H. Kawaharada, and K. Watanabe.
1990.
Comparison of human lymphotoxin gene expression in CHO cells directed by genomic DNA or cDNA sequences.
Agric. Biol. Chem.
54:2801-2809[Medline].
|
| 44.
| Yamashita, K., et al. Unpublished data.
|
Infection and Immunity, June 1999, p. 3175-3179, Vol. 67, No. 6
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Vanover, J., Sun, J., Deka, S., Kintner, J., Duffourc, M. M., Schoborg, R. V.
(2008). Herpes simplex virus co-infection-induced Chlamydia trachomatis persistence is not mediated by any known persistence inducer or anti-chlamydial pathway. Microbiology
154: 971-978
[Abstract]
[Full Text]
-
Sakai, K., Suzuki, H., Oda, H., Akaike, T., Azuma, Y., Murakami, T., Sugi, K., Ito, T., Ichinose, H., Koyasu, S., Shirai, M.
(2006). Phosphoinositide 3-Kinase in Nitric Oxide Synthesis in Macrophage: CRITICAL DIMERIZATION OF INDUCIBLE NITRIC-OXIDE SYNTHASE. J. Biol. Chem.
281: 17736-17742
[Abstract]
[Full Text]
-
Azuma, Y., Hirakawa, H., Yamashita, A., Cai, Y., Rahman, M. A., Suzuki, H., Mitaku, S., Toh, H., Goto, S., Murakami, T., Sugi, K., Hayashi, H., Fukushi, H., Hattori, M., Kuhara, S., Shirai, M.
(2006). Genome Sequence of the Cat Pathogen, Chlamydophila felis. DNA Res
13: 15-23
[Abstract]
[Full Text]
-
Rahman, Mohd. A., Azuma, Y., Fukunaga, H., Murakami, T., Sugi, K., Fukushi, H., Miura, K., Suzuki, H., Shirai, M.
(2005). Serotonin and melatonin, neurohormones for homeostasis, as novel inhibitors of infections by the intracellular parasite chlamydia. J Antimicrob Chemother
56: 861-868
[Abstract]
[Full Text]
-
Yoneda, H., Miura, K., Matsushima, H., Sugi, K., Murakami, T., Ouchi, K., Yamashita, K., Itoh, H., Nakazawa, T., Suzuki, M., Shirai, M.
(2003). Aspirin inhibits Chlamydia pneumoniae-induced NF-{kappa}B activation, cyclo-oxygenase-2 expression and prostaglandin E2 synthesis and attenuates chlamydial growth. J Med Microbiol
52: 409-415
[Abstract]
[Full Text]
-
Yang, J., Hooper, W. C., Phillips, D. J., Tondella, M. L., Talkington, D. F.
(2003). Induction of Proinflammatory Cytokines in Human Lung Epithelial Cells during Chlamydia pneumoniae Infection. Infect. Immun.
71: 614-620
[Abstract]
[Full Text]
-
Tiran, A., Gruber, H.-J., Graier, W. F., Wagner, A. H., van Leeuwen, E. B.M., Tiran, B.
(2002). Aspirin Inhibits Chlamydia pneumoniae-Induced Nuclear Factor-{kappa}B Activation, Cytokine Expression, and Bacterial Development in Human Endothelial Cells. Arterioscler. Thromb. Vasc. Bio.
22: 1075-1080
[Abstract]
[Full Text]
-
Roach, D. R., Bean, A. G. D., Demangel, C., France, M. P., Briscoe, H., Britton, W. J.
(2002). TNF Regulates Chemokine Induction Essential for Cell Recruitment, Granuloma Formation, and Clearance of Mycobacterial Infection. J. Immunol.
168: 4620-4627
[Abstract]
[Full Text]
-
Prebeck, S., Kirschning, C., Durr, S., da Costa, C., Donath, B., Brand, K., Redecke, V., Wagner, H., Miethke, T.
(2001). Predominant Role of Toll-Like Receptor 2 Versus 4 in Chlamydia pneumoniae-Induced Activation of Dendritic Cells. J. Immunol.
167: 3316-3323
[Abstract]
[Full Text]
-
Roach, D. R., Briscoe, H., Saunders, B., France, M. P., Riminton, S., Britton, W. J.
(2001). Secreted Lymphotoxin-{alpha} Is Essential for the Control of an Intracellular Bacterial Infection. JEM
193: 239-246
[Abstract]
[Full Text]
-
Miura, K., Inouye, S., Sakai, K., Takaoka, H., Kishi, F., Tabuchi, M., Tanaka, T., Matsumoto, H., Shirai, M., Nakazawa, T., Nakazawa, A.
(2001). Cloning and Characterization of Adenylate Kinase from Chlamydia pneumoniae. J. Biol. Chem.
276: 13490-13498
[Abstract]
[Full Text]